News

Celestica's Earnings Preview: What Investors Should Know

Celestica's Earnings Preview: What Investors Should Know

Understanding Celestica's Earnings Expectations

Celestica (NYSE: CLS) is set to announce its quarterly earnings soon, and investors are eager to know what to expect. Analysts predict that the company will report an earnings per share (EPS) of $0.93. This upcoming announcement is particularly important as it can impact investor sentiment and stock price movements significantly.

Before the earnings release, it is crucial for investors to consider not just the EPS number, but also guidance provided by the company. Guidance can offer insights into future expectations and can often influence trading behavior in the days following the announcement.

Reviewing Past Earnings Performance

In the previous quarter, Celestica reported an EPS that beat expectations by $0.10. Interestingly, even with this positive announcement, the share price dropped by 4.35% on the next trading day. This instance underlines the unpredictable nature of market reactions and how critical guidance can be for stock performance.

To provide more context, let’s take a look at some historical earnings data:

During the last few quarters, the EPS performance has varied significantly:

Performance Metrics Over Recent Quarters

As we analyze past results, here are the highlights:

  • Q2 2024 - EPS Estimate: 0.81, EPS Actual: 0.91, Price Change: -4.0%
  • Q1 2024 - EPS Estimate: 0.72, EPS Actual: 0.86, Price Change: -2.0%
  • Q4 2023 - EPS Estimate: 0.68, EPS Actual: 0.76, Price Change: 2.0%
  • Q3 2023 - EPS Estimate: 0.60, EPS Actual: 0.65, Price Change: -10.0%

These numbers illustrate the company's mixed performance in achieving estimates and the subsequent effects on stock price, reflecting the importance of market expectations.

Current Stock Performance

As of the latest quotes, Celestica shares traded at $56.68. Over the past year, the stock has experienced remarkable growth, boasting a 122.8% increase. Such positive movement often inspires confidence among long-term investors regarding potential upward trajectories.

Insights From Analysts

Understanding market sentiment is crucial for making informed investment decisions. Analysts currently have a positive outlook on Celestica, with a consensus rating of Buy based on six available ratings. The average one-year price target stands at $63.17, suggesting an attractive upside potential of 11.45% for prospective investors.

Comparative Analysis With Industry Peers

To better understand Celestica's positioning within the sector, it is beneficial to compare it with some notable competitors:

  • Fabrinet: Analysts rate it Neutral with an average one-year price target of $256.20, indicating a potential upside of 352.01%.
  • Plexus: Analysts suggest a Buy with a price target of $147.25, representing a potential upside of 159.79%.
  • IPG Photonics: Analysts also rate it Buy, with a target of $100.00, implying a 76.43% upside.

Performance Metrics Compared

Taking a closer look at the metrics of various companies offers a deeper understanding:

  • Celestica: Consensus: Buy, Revenue Growth: 23.33%, Gross Profit: $256.10M, Return on Equity: 5.67%
  • Fabrinet: Consensus: Neutral, Revenue Growth: 14.85%, Gross Profit: $92.45M, Return on Equity: 4.76%
  • Plexus: Consensus: Buy, Revenue Growth: -5.96%, Gross Profit: $94.42M, Return on Equity: 1.99%
  • IPG Photonics: Consensus: Buy, Revenue Growth: -24.22%, Gross Profit: $96.19M, Return on Equity: 0.88%

Celestica stands out with strong revenue growth and gross profit margins, although it trails in return on equity relative to its peers.

Exploring Celestica's Core Business

Celestica Inc specializes in supply chain solutions, operating through two main segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment services various industries, including aerospace, defense, and health technology. Meanwhile, the CCS segment focuses on communications and enterprise solutions, contributing significantly to the company's revenue stream.

Analyzing Celestica's Economic Impact

Examining Celestica's performance metrics reveals a strong market presence:

  • Market Capitalization: Celestica enjoys a market capitalization that exceeds the industry average.
  • Revenue Growth: An impressive growth rate of 23.33% illustrates the company’s strong top-line performance.
  • Net Margin: With a net margin of 4.16%, Celestica exhibits robust profitability.
  • Return on Equity: With a ROE of 5.67%, the company shows efficient management of shareholder equity.
  • Return on Assets: A strong ROA of 1.72% indicates effective asset utilization.
  • Debt Management: The company maintains a healthy debt-to-equity ratio of 0.53, demonstrating prudent financial management.

Overall, Celestica is positioned strongly within its industry, showcasing a balance of revenue growth, market presence, and effective management practices.

Frequently Asked Questions

1. What is the expected EPS for Celestica this quarter?

The expected earnings per share (EPS) for Celestica this quarter is $0.93.

2. How have Celestica's shares performed over the past year?

Celestica's shares have risen by 122.8% over the last 52 weeks, reflecting strong performance.

3. What is the consensus rating for Celestica?

The consensus rating for Celestica among analysts is Buy, based on six ratings.

4. How does Celestica compare to its industry peers?

Celestica leads in revenue growth and gross profit margins compared to its peers, although it has a lower return on equity.

5. What are Celestica's core business segments?

Celestica operates in two main segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS).

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 4

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 2

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 1

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 3

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 3

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 6

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 2

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

ANI Pharmaceuticals Executive Stock Sale Sparks Investor Interest

Updated Category News Views 53

Stock Sale by ANI Pharmaceuticals Executive ANI Pharmaceuticals Inc. (NASDAQ: ANIP) has recently gained attention due to a notable stock transaction involving one of its high-ranking officials. Meredith Cook, who serves as the Senior Vice President, General Counsel, and Secretary at the company, sold 250 shares of common stock. This sale, which amounted to about $14,205,...

Continue Reading
Welcoming Dr. Morales: A New Era for NewHydrogen's Innovation

Updated Category News Views 174

Welcoming Dr. Austin Morales to NewHydrogen Dr. Morales brings expertise in dynamic reactor operation and advanced catalytic processes. NewHydrogen, Inc. (OTCQB: NEWH), a pioneer in clean hydrogen technologies, is thrilled to announce Dr. Austin Morales’ addition to its talented UCSB Technology Team. With his extensive background in catalytic processes and reactor...

Continue Reading
42com Expands its Telecom Services in Italy with New Offerings

Updated Category News Views 111

42com Launches New ISP and Satellite Infrastructure Services 42com has dramatically expanded its service portfolio with the acquisition of assets from Milano Teleport Srl. This move has enabled the company to introduce valuable new services, including 24/7 Network Operations Center (NOC) support for LEO, VSAT, 5G, and IoT technologies. Establishing a Strong Presence in...

Continue Reading
AI Professionals Face Major Gaps in Tools and Confidence

Updated Category News Views 85

Understanding the Current Landscape of AI Professionals A recent survey unveiled concerning insights into the AI landscape, revealing that a mere 34% of AI professionals feel fully prepared to tackle the challenges associated with their organizations' AI objectives. This stark finding indicates a growing tension between AI investments and actual readiness within companies...

Continue Reading
Brazil's Meal Vouchers Market Poised for Growth with AI Insights

Updated Category News Views 513

Brazil's Meal Vouchers Market Poised for Growth The market for meal vouchers and employee benefit solutions in Brazil is projected to experience remarkable growth, with estimates indicating an increase of USD 9.96 billion from 2025 to 2029. This growth is largely fueled by the advantages offered by tax benefits and AI-driven innovations. As organizations search for ways...

Continue Reading